<?xml version='1.0' encoding='utf-8'?>
<document id="27638508"><sentence text="Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans." /><sentence text="This study was a comprehensive analysis of metabolites in plasma and urine specimens from subjects who received probenecid, a potent inhibitor of renal organic anion transporters (OATs)" /><sentence text=" Taurine and glycochenodeoxycholate sulfate (GCDCA-S) could be identified using authentic standards"><entity charOffset="1-8" id="DDI-PubMed.27638508.s3.e0" text="Taurine" /><entity charOffset="13-43" id="DDI-PubMed.27638508.s3.e1" text="glycochenodeoxycholate sulfate" /><entity charOffset="45-52" id="DDI-PubMed.27638508.s3.e2" text="GCDCA-S" /><pair ddi="false" e1="DDI-PubMed.27638508.s3.e0" e2="DDI-PubMed.27638508.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27638508.s3.e0" e2="DDI-PubMed.27638508.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27638508.s3.e0" e2="DDI-PubMed.27638508.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27638508.s3.e1" e2="DDI-PubMed.27638508.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27638508.s3.e1" e2="DDI-PubMed.27638508.s3.e2" /></sentence><sentence text=" Probenecid had no effect on the area under the plasma-concentration time curves of taurine and GCDCA-S, whereas it significantly inhibited their urinary excretion in a dose-dependent manner"><entity charOffset="1-11" id="DDI-PubMed.27638508.s4.e0" text="Probenecid" /><entity charOffset="84-91" id="DDI-PubMed.27638508.s4.e1" text="taurine" /><entity charOffset="96-103" id="DDI-PubMed.27638508.s4.e2" text="GCDCA-S" /><pair ddi="false" e1="DDI-PubMed.27638508.s4.e0" e2="DDI-PubMed.27638508.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27638508.s4.e0" e2="DDI-PubMed.27638508.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27638508.s4.e0" e2="DDI-PubMed.27638508.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27638508.s4.e1" e2="DDI-PubMed.27638508.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27638508.s4.e1" e2="DDI-PubMed.27638508.s4.e2" /></sentence><sentence text=" Probenecid at 500, 750, and 1500 mg orally decreased the renal clearance (CLR) values of taurine and GCDCA-S by 45% and 60%, 59% and 79%, and 70% and 88%, respectively"><entity charOffset="1-11" id="DDI-PubMed.27638508.s5.e0" text="Probenecid" /><entity charOffset="90-97" id="DDI-PubMed.27638508.s5.e1" text="taurine" /><pair ddi="false" e1="DDI-PubMed.27638508.s5.e0" e2="DDI-PubMed.27638508.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27638508.s5.e0" e2="DDI-PubMed.27638508.s5.e1" /></sentence><sentence text=" The CLR values correlated strongly (r &gt; 0" /><sentence text="96) between the test compounds (benzylpenicillin, 6β-hydroxycortisol, taurine, and GCDCA-S)"><entity charOffset="32-48" id="DDI-PubMed.27638508.s7.e0" text="benzylpenicillin" /><entity charOffset="50-68" id="DDI-PubMed.27638508.s7.e1" text="6β-hydroxycortisol" /><entity charOffset="70-77" id="DDI-PubMed.27638508.s7.e2" text="taurine" /><pair ddi="false" e1="DDI-PubMed.27638508.s7.e0" e2="DDI-PubMed.27638508.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27638508.s7.e0" e2="DDI-PubMed.27638508.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27638508.s7.e0" e2="DDI-PubMed.27638508.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27638508.s7.e1" e2="DDI-PubMed.27638508.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27638508.s7.e1" e2="DDI-PubMed.27638508.s7.e2" /></sentence><sentence text=" Taurine and GCDCA-S were substrates of OAT1 and OAT3, with Km values of 379 ± 58 and 64"><entity charOffset="1-8" id="DDI-PubMed.27638508.s8.e0" text="Taurine" /></sentence><sentence text="3 ± 3" /><sentence text="9 μM, respectively" /><sentence text=" The Ki values of probenecid for the OAT1- and OAT3-mediated uptake of taurine and GCDCA-S (9"><entity charOffset="18-28" id="DDI-PubMed.27638508.s11.e0" text="probenecid" /><entity charOffset="37-42" id="DDI-PubMed.27638508.s11.e1" text="OAT1-" /><entity charOffset="71-78" id="DDI-PubMed.27638508.s11.e2" text="taurine" /><entity charOffset="83-90" id="DDI-PubMed.27638508.s11.e3" text="GCDCA-S" /><pair ddi="false" e1="DDI-PubMed.27638508.s11.e0" e2="DDI-PubMed.27638508.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27638508.s11.e0" e2="DDI-PubMed.27638508.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27638508.s11.e0" e2="DDI-PubMed.27638508.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27638508.s11.e0" e2="DDI-PubMed.27638508.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27638508.s11.e1" e2="DDI-PubMed.27638508.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27638508.s11.e1" e2="DDI-PubMed.27638508.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27638508.s11.e1" e2="DDI-PubMed.27638508.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27638508.s11.e2" e2="DDI-PubMed.27638508.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27638508.s11.e2" e2="DDI-PubMed.27638508.s11.e3" /></sentence><sentence text="49 ± 1" /><sentence text="27 and 7" /><sentence text="40 ± 0" /><sentence text="70 μM, respectively) were similar to those of their typical substrate drugs" /><sentence text=" The magnitude of the reduction in the CLR of taurine and GCDCA-S by probenecid could be reasonably explained using the geometric mean values of unbound probenecid concentration and Ki values"><entity charOffset="46-53" id="DDI-PubMed.27638508.s16.e0" text="taurine" /><entity charOffset="69-79" id="DDI-PubMed.27638508.s16.e1" text="probenecid" /><pair ddi="false" e1="DDI-PubMed.27638508.s16.e0" e2="DDI-PubMed.27638508.s16.e0" /><pair ddi="false" e1="DDI-PubMed.27638508.s16.e0" e2="DDI-PubMed.27638508.s16.e1" /></sentence><sentence text=" These results suggest that taurine and GCDCA-S can be used as probes for evaluating pharmacokinetic drug-drug interactions involving OAT1 and OAT3, respectively, in humans"><entity charOffset="28-35" id="DDI-PubMed.27638508.s17.e0" text="taurine" /><entity charOffset="40-47" id="DDI-PubMed.27638508.s17.e1" text="GCDCA-S" /><pair ddi="false" e1="DDI-PubMed.27638508.s17.e0" e2="DDI-PubMed.27638508.s17.e0" /><pair ddi="false" e1="DDI-PubMed.27638508.s17.e0" e2="DDI-PubMed.27638508.s17.e1" /></sentence><sentence text="" /></document>